Instrument Inactif

Autres langues Lightlake Therapeutics OTC Bulletin Board

Actions

US53224T1051

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

2023	Indivior complète l'acquisition d'Opiant Pharmaceuticals	AN
2023	Indivior conclut l'accord d'achat d'Opiant Pharmaceuticals	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Indivior completes acquisition of Opiant Pharmaceuticals	02/03/23
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	02/03/23
OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	02/03/23
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	02/03/23
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	02/03/23
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	02/03/23
OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	01/03/23
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	27/02/23
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	08/02/23
OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	07/02/23
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	07/02/23
Bolsa de Madrid: Jerome vuelve en la segunda semana	07/02/23
Indivior announces expiry of waiting period for Opiant purchase	06/02/23
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	06/02/23
Indivior Nears Acquisition of Opiant Pharmaceuticals	06/02/23
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	06/02/23
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	06/02/23
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	26/01/23
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	20/01/23
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	19/01/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lightlake Therapeutics OTC Bulletin Board

Actions

US53224T1051

Autres langues

Filtres